Abstract
Summary
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
The global Pneumococcal Vaccine market is projected to reach US$ 7780.4 million by 2030 from an estimated US$ 7286.1 million in 2024, at a CAGR of 1.1% during 2024 and 2030.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Pneumococcal Vaccine.
The Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Vaccine market comprehensively. Regional market sizes, concerning products by type, by end user, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by end user, and regions.
Market Segmentation
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by End User
Child
Adult
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by End User, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Pneumococcal Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Vaccine sales, revenue, price, gross margin, sales by region, by Type, by End User, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by End User, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by End User and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by End User and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by End User and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by End User and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by End User and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
The global Pneumococcal Vaccine market is projected to reach US$ 7780.4 million by 2030 from an estimated US$ 7286.1 million in 2024, at a CAGR of 1.1% during 2024 and 2030.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pneumococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Pneumococcal Vaccine.
The Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pneumococcal Vaccine market comprehensively. Regional market sizes, concerning products by type, by end user, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pneumococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by end user, and regions.
Market Segmentation
By Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Segment by Type
PPSV 23
PCV 7/13
PCV 10
Segment by End User
Child
Adult
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by End User, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Pneumococcal Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Vaccine sales, revenue, price, gross margin, sales by region, by Type, by End User, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by End User, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by End User and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by End User and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by End User and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by End User and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by End User and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Table of Contents
1 Study Coverage
1.1 Pneumococcal Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Pneumococcal Vaccine Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 PPSV 23
1.2.3 PCV 7/13
1.2.4 PCV 10
1.3 Market by End User
1.3.1 Global Pneumococcal Vaccine Market Size Growth Rate by End User (2019 VS 2023 VS 2030)
1.3.2 Child
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Pneumococcal Vaccine Market Size Estimates and Forecasts
2.1.1 Global Pneumococcal Vaccine Revenue 2019-2030
2.1.2 Global Pneumococcal Vaccine Sales 2019-2030
2.2 Pneumococcal Vaccine Market Size by Region: 2023 Versus 2030
2.3 Pneumococcal Vaccine Sales by Region (2019-2030)
2.3.1 Global Pneumococcal Vaccine Sales by Region: 2019-2024
2.3.2 Global Pneumococcal Vaccine Sales Forecast by Region (2025-2030)
2.3.3 Global Pneumococcal Vaccine Sales Market Share by Region (2019-2030)
2.4 Pneumococcal Vaccine Market Estimates and Projections by Region (2025-2030)
2.4.1 Global Pneumococcal Vaccine Revenue by Region: 2019-2024
2.4.2 Global Pneumococcal Vaccine Revenue Forecast by Region (2025-2030)
2.4.3 Global Pneumococcal Vaccine Revenue Market Share by Region (2019-2030)
3 Global Pneumococcal Vaccine by Manufacturers
3.1 Global Top Pneumococcal Vaccine Manufacturers by Sales
3.1.1 Global Pneumococcal Vaccine Sales by Manufacturer (2019-2024)
3.1.2 Global Pneumococcal Vaccine Sales Market Share by Manufacturer (2019-2024)
3.2 Global Top Pneumococcal Vaccine Manufacturers by Revenue
3.2.1 Global Pneumococcal Vaccine Revenue by Manufacturer (2019-2024)
3.2.2 Global Pneumococcal Vaccine Revenue Share by Manufacturer (2019-2024)
3.3 Global Pneumococcal Vaccine Price by Manufacturer (2019-2024)
3.4 Competitive Landscape
3.4.1 Key Pneumococcal Vaccine Manufacturers Covered: Ranking by Revenue
3.4.2 Global Pneumococcal Vaccine Market Concentration Ratio (CR5 and HHI) & (2019-2024)
3.4.3 Global Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Pneumococcal Vaccine Manufacturing Base Distribution, Product Type
3.5.1 Pneumococcal Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Pneumococcal Vaccine Product Type
3.5.3 Date of International Manufacturers Enter into Pneumococcal Vaccine Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Pfizer
4.1.1 Pfizer Company Information
4.1.2 Pfizer Description, Business Overview
4.1.3 Pfizer Pneumococcal Vaccine Products Offered
4.1.4 Pfizer Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.1.5 Pfizer Pneumococcal Vaccine Sales by Product in 2023
4.1.6 Pfizer Pneumococcal Vaccine Sales by End User in 2023
4.1.7 Pfizer Pneumococcal Vaccine Sales by Geographic Area in 2023
4.1.8 Pfizer Recent Developments
4.2 GSK
4.2.1 GSK Company Information
4.2.2 GSK Description, Business Overview
4.2.3 GSK Pneumococcal Vaccine Products Offered
4.2.4 GSK Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.2.5 GSK Pneumococcal Vaccine Sales by Product in 2023
4.2.6 GSK Pneumococcal Vaccine Sales by End User in 2023
4.2.7 GSK Pneumococcal Vaccine Sales by Geographic Area in 2023
4.2.8 GSK Recent Developments
4.3 MSD
4.3.1 MSD Company Information
4.3.2 MSD Description, Business Overview
4.3.3 MSD Pneumococcal Vaccine Products Offered
4.3.4 MSD Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.3.5 MSD Pneumococcal Vaccine Sales by Product in 2023
4.3.6 MSD Pneumococcal Vaccine Sales by End User in 2023
4.3.7 MSD Pneumococcal Vaccine Sales by Geographic Area in 2023
4.3.8 MSD Recent Developments
4.4 Sanofipasteur
4.4.1 Sanofipasteur Company Information
4.4.2 Sanofipasteur Description, Business Overview
4.4.3 Sanofipasteur Pneumococcal Vaccine Products Offered
4.4.4 Sanofipasteur Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.4.5 Sanofipasteur Pneumococcal Vaccine Sales by Product in 2023
4.4.6 Sanofipasteur Pneumococcal Vaccine Sales by End User in 2023
4.4.7 Sanofipasteur Pneumococcal Vaccine Sales by Geographic Area in 2023
4.4.8 Sanofipasteur Recent Developments
4.5 CDIBP
4.5.1 CDIBP Company Information
4.5.2 CDIBP Description, Business Overview
4.5.3 CDIBP Pneumococcal Vaccine Products Offered
4.5.4 CDIBP Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
4.5.5 CDIBP Pneumococcal Vaccine Sales by Product in 2023
4.5.6 CDIBP Pneumococcal Vaccine Sales by End User in 2023
4.5.7 CDIBP Pneumococcal Vaccine Sales by Geographic Area in 2023
4.5.8 CDIBP Recent Developments
5 Breakdown Data by Type
5.1 Global Pneumococcal Vaccine Sales by Type (2019-2030)
5.1.1 Global Pneumococcal Vaccine Sales by Type (2019-2024)
5.1.2 Global Pneumococcal Vaccine Sales Forecast by Type (2025-2030)
5.1.3 Global Pneumococcal Vaccine Sales Market Share by Type (2019-2030)
5.2 Global Pneumococcal Vaccine Revenue Forecast by Type (2019-2030)
5.2.1 Global Pneumococcal Vaccine Revenue by Type (2019-2024)
5.2.2 Global Pneumococcal Vaccine Revenue Forecast by Type (2025-2030)
5.2.3 Global Pneumococcal Vaccine Revenue Market Share by Type (2019-2030)
5.3 Pneumococcal Vaccine Average Selling Price (ASP) by Type (2019-2030)
6 Breakdown Data by End User
6.1 Global Pneumococcal Vaccine Sales by End User (2019-2030)
6.1.1 Global Pneumococcal Vaccine Sales by End User (2019-2024)
6.1.2 Global Pneumococcal Vaccine Sales Forecast by End User (2025-2030)
6.1.3 Global Pneumococcal Vaccine Sales Market Share by End User (2019-2030)
6.2 Global Pneumococcal Vaccine Revenue Forecast by End User (2019-2030)
6.2.1 Global Pneumococcal Vaccine Revenue by End User (2019-2024)
6.2.2 Global Pneumococcal Vaccine Revenue Forecast by End User (2025-2030)
6.2.3 Global Pneumococcal Vaccine Revenue Market Share by End User (2019-2030)
6.3 Pneumococcal Vaccine Average Selling Price (ASP) by End User (2019-2030)
7 North America
7.1 North America Pneumococcal Vaccine Market Size YoY Growth 2019-2030
7.2 North America Pneumococcal Vaccine Market Facts & Figures by Country
7.2.1 North America Pneumococcal Vaccine Sales by Country (2019-2030)
7.2.2 North America Pneumococcal Vaccine Revenue by Country (2019-2030)
7.3 North America Pneumococcal Vaccine Sales by Type (2019-2024)
7.4 North America Pneumococcal Vaccine Sales by End User (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Pneumococcal Vaccine Market Size YoY Growth 2019-2030
8.2 Asia-Pacific Pneumococcal Vaccine Market Facts & Figures by Region
8.2.1 Asia-Pacific Pneumococcal Vaccine Sales by Region (2019-2030)
8.2.2 Asia-Pacific Pneumococcal Vaccine Revenue by Region (2019-2030)
8.3 Asia-Pacific Pneumococcal Vaccine Sales by Type (2019-2024)
8.4 Asia-Pacific Pneumococcal Vaccine Sales by End User (2019-2024)
9 Europe
9.1 Europe Pneumococcal Vaccine Market Size YoY Growth 2019-2030
9.2 Europe Pneumococcal Vaccine Market Facts & Figures by Country
9.2.1 Europe Pneumococcal Vaccine Sales by Country (2019-2030)
9.2.2 Europe Pneumococcal Vaccine Revenue by Country (2019-2030)
9.3 Europe Pneumococcal Vaccine Sales by Type (2019-2024)
9.4 Europe Pneumococcal Vaccine Sales by End User (2019-2024)
10 Latin America
10.1 Latin America Pneumococcal Vaccine Market Size YoY Growth 2019-2030
10.2 Latin America Pneumococcal Vaccine Market Facts & Figures by Country
10.2.1 Latin America Pneumococcal Vaccine Sales by Country (2019-2030)
10.2.2 Latin America Pneumococcal Vaccine Revenue by Country (2019-2030)
10.3 Latin America Pneumococcal Vaccine Sales by Type (2019-2024)
10.4 Latin America Pneumococcal Vaccine Sales by End User (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Pneumococcal Vaccine Market Size YoY Growth 2019-2030
11.2 Middle East and Africa Pneumococcal Vaccine Market Facts & Figures by Country
11.2.1 Middle East and Africa Pneumococcal Vaccine Sales by Country (2019-2030)
11.2.2 Middle East and Africa Pneumococcal Vaccine Revenue by Country (2019-2030)
11.3 Middle East and Africa Pneumococcal Vaccine Sales by Type (2019-2024)
11.4 Middle East and Africa Pneumococcal Vaccine Sales by End User (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Pneumococcal Vaccine Supply Chain Analysis
12.2 Pneumococcal Vaccine Key Raw Materials and Upstream Suppliers
12.3 Pneumococcal Vaccine Clients Analysis
12.4 Pneumococcal Vaccine Sales Channel and Sales Model Analysis
12.4.1 Pneumococcal Vaccine Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Pneumococcal Vaccine Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Pneumococcal Vaccine Distributors
13 Market Dynamics
13.1 Pneumococcal Vaccine Industry Trends
13.2 Pneumococcal Vaccine Market Drivers
13.3 Pneumococcal Vaccine Market Challenges
13.4 Pneumococcal Vaccine Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer